{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:40:01Z","timestamp":1748594401564,"version":"3.41.0"},"reference-count":33,"publisher":"Japanese Society of Veterinary Science","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Veterinary Medical Science","J. Vet. Med. Sci."],"published-print":{"date-parts":[[2016]]},"DOI":"10.1292\/jvms.15-0195","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T22:05:33Z","timestamp":1440799533000},"page":"77-82","source":"Crossref","is-referenced-by-count":0,"title":["Prophylactic treatment with sulphonated immunoglobulin G attenuates development of mechanical allodynia-like response in mice with neuropathic pain"],"prefix":"10.1292","volume":"78","author":[{"given":"Wataru","family":"YAMAMOTO","sequence":"first","affiliation":[{"name":"Pharmaceutical Development Research Laboratories, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Tokyo 191\u20138512, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"ITANO","sequence":"additional","affiliation":[{"name":"Pharmaceutical Development Research Laboratories, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Tokyo 191\u20138512, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunefumi","family":"KOBAYASHI","sequence":"additional","affiliation":[{"name":"Pharmaceutical Development Research Laboratories, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Tokyo 191\u20138512, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daishiro","family":"MIURA","sequence":"additional","affiliation":[{"name":"Pharmaceutical Development Research Laboratories, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Tokyo 191\u20138512, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"KASAHARA","sequence":"additional","affiliation":[{"name":"Pharmaceutical Development Research Laboratories, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Tokyo 191\u20138512, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"122","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Abbadie, C., Lindia, J. A., Cumiskey, A. M., Peterson, L. B., Mudgett, J. S., Bayne, E. K., DeMartino, J. A., MacIntyre, D. E. and Forrest, M. J. 2003. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i> 100: 7947\u20137952.","DOI":"10.1073\/pnas.1331358100"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Achiron, A., Gabbay, U., Gilad, R., Hassin-Baer, S., Barak, Y., Gornish, M., Elizur, A., Goldhammer, Y. and Sarova-Pinhas, I. 1998. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. <i>Neurology<\/i> 50: 398\u2013402.","DOI":"10.1212\/WNL.50.2.398"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Basta, M., Kirshbom, P., Frank, M. M. and Fries, L. F. 1989. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. <i>J. Clin. Invest.<\/i> 84: 1974\u20131981.","DOI":"10.1172\/JCI114387"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Czeschik, J. C., Hagenacker, T., Schafers, M. and Busselberg, D. 2008. TNF-alpha differentially modulates ion channels of nociceptive neurons. <i>Neurosci. Lett.<\/i> 434: 293\u2013298.","DOI":"10.1016\/j.neulet.2008.01.070"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Fujii, Y., Kitaura, K., Nakamichi, K., Takasaki, T., Suzuki, R. and Kurane, I. 2008. Accumulation of T-cells with selected T-cell receptors in the brains of Japanese encephalitis virus-infected mice. <i>Jpn. J. Infect. Dis.<\/i> 61: 40\u201348.","DOI":"10.7883\/yoken.JJID.2008.40"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Goebel, A., Baranowski, A., Maurer, K., Ghiai, A., McCabe, C. and Ambler, G. 2010. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. <i>Ann. Intern. Med.<\/i> 152: 152\u2013158.","DOI":"10.7326\/0003-4819-152-3-201002020-00006"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gold, R., Stangel, M. and Dalakas, M. C. 2007. Drug insight: the use of intravenous immunoglobulin in neurology\u2013therapeutic considerations and practical issues. <i>Nat. Clin. Pract. Neurol.<\/i> 3: 36\u201344.","DOI":"10.1038\/ncpneuro0376"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Horiuchi, A., Abe, Y., Miyake, M., Osuka, Y. and Kimura, S. 1993. Natural human IgG inhibits the production of tumor necrosis factor-alpha and interleukin-1 alpha through the Fc portion. <i>Surg. Today<\/i> 23: 241\u2013245.","DOI":"10.1007\/BF00309234"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kiguchi, N., Kobayashi, Y., Saika, F. and Kishioka, S. 2013. Epigenetic upregulation of CCL2 and CCL3 via histone modifications in infiltrating macrophages after peripheral nerve injury. <i>Cytokine<\/i> 64: 666\u2013672.","DOI":"10.1016\/j.cyto.2013.09.019"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kiguchi, N., Maeda, T., Kobayashi, Y., Fukazawa, Y. and Kishioka, S. 2010. Macrophage inflammatory protein-1alpha mediates the development of neuropathic pain following peripheral nerve injury through interleukin-1beta up-regulation. <i>Pain<\/i> 149: 305\u2013315.","DOI":"10.1016\/j.pain.2010.02.025"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kishimoto, C., Takada, H., Kawamata, H., Umatake, M. and Ochiai, H. 2001. Immunoglobulin treatment prevents congestive heart failure in murine encephalomyocarditis viral myocarditis associated with reduction of inflammatory cytokines. <i>J. Pharmacol. Exp. Ther.<\/i> 299: 645\u2013651.","DOI":"10.1016\/S0022-3565(24)29273-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Klein, C. J., Lennon, V. A., Aston, P. A., McKeon, A. and Pittock, S. J. 2012. Chronic pain as a manifestation of potassium channel-complex autoimmunity. <i>Neurology<\/i> 79: 1136\u20131144.","DOI":"10.1212\/WNL.0b013e3182698cab"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kohr, D., Singh, P., Tschernatsch, M., Kaps, M., Pouokam, E., Diener, M., Kummer, W., Birklein, F., Vincent, A., Goebel, A., Wallukat, G. and Blaes, F. 2011. Autoimmunity against the beta2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. <i>Pain<\/i> 152: 2690\u20132700.","DOI":"10.1016\/j.pain.2011.06.012"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lapointe, B. M., Herx, L. M., Gill, V., Metz, L. M. and Kubes, P. 2004. IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. <i>Brain<\/i> 127: 2649\u20132656.","DOI":"10.1093\/brain\/awh297"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Malmberg, A. B. and Basbaum, A. I. 1998. Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. <i>Pain<\/i> 76: 215\u2013222.","DOI":"10.1016\/S0304-3959(98)00045-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Masuho, Y., Tomibe, K., Matsuzawa, K. and Ohtsu, A. 1977. Development of an intravenous gamma-globulin with Fc activities. I. Preparation and characterization of S-sulfonated human gamma-globulin. <i>Vox Sang.<\/i> 32: 175\u2013181.","DOI":"10.1111\/j.1423-0410.1977.tb00622.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Masuho, Y., Tomibe, K., Watanabe, T. and Fukumoto, Y. 1977. Development of an intravenous gamma-globulin with Fc activities. II. Reconversion of S-sulfonated human gamma-globulin into the original gamma-globulin. <i>Vox Sang.<\/i> 32: 290\u2013295.","DOI":"10.1111\/j.1423-0410.1977.tb00648.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. McQuay, H. J., Tramer, M., Nye, B. A., Carroll, D., Wiffen, P. J. and Moore, R. A. 1996. A systematic review of antidepressants in neuropathic pain. <i>Pain<\/i> 68: 217\u2013227.","DOI":"10.1016\/S0304-3959(96)03140-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Morozumi, S., Kawagashira, Y., Iijima, M., Koike, H., Hattori, N., Katsuno, M., Tanaka, F. and Sobue, G. 2009. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjogren\u2019s syndrome. <i>J. Neurol. Sci.<\/i> 279: 57\u201361.","DOI":"10.1016\/j.jns.2008.12.018"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Nadeau, S., Filali, M., Zhang, J., Kerr, B. J., Rivest, S., Soulet, D., Iwakura, Y., de Rivero Vaccari, J. P., Keane, R. W. and Lacroix, S. 2011. Functional recovery after peripheral nerve injury is dependent on the pro-inflammatory cytokines IL-1beta and TNF: implications for neuropathic pain. <i>J. Neurosci.<\/i> 31: 12533\u201312542.","DOI":"10.1523\/JNEUROSCI.2840-11.2011"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Seltzer, Z., Dubner, R. and Shir, Y. 1990. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. <i>Pain<\/i> 43: 205\u2013218.","DOI":"10.1016\/0304-3959(90)91074-S"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Shoenfeld, Y. and Katz, U. 2005. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. <i>Autoimmunity<\/i> 38: 123\u2013137.","DOI":"10.1080\/08916930500059633"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sindrup, S. H. and Jensen, T. S. 1999. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. <i>Pain<\/i> 83: 389\u2013400.","DOI":"10.1016\/S0304-3959(99)00154-2"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sommer, C., Schafers, M., Marziniak, M. and Toyka, K. V. 2001. Etanercept reduces hyperalgesia in experimental painful neuropathy. <i>J. Peripher. Nerv. Syst.<\/i> 6: 67\u201372.","DOI":"10.1046\/j.1529-8027.2001.01010.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Tamburin, S., Borg, K., Caro, X. J., Jann, S., Clark, A. J., Magrinelli, F., Sobue, G., Werhagen, L., Zanette, G., Koike, H., Spath, P. J., Vincent, A. and Goebel, A. 2014. Immunoglobulin g for the treatment of chronic pain: report of an expert workshop. <i>Pain Med.<\/i> 15: 1072\u20131082.","DOI":"10.1111\/pme.12319"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Tamburin, S., Magrinelli, F., Favaro, F., Briani, C. and Zanette, G. 2014. Long-term response of neuropathic pain to intravenous immunoglobulin in relapsing diabetic lumbosacral radiculoplexus neuropathy. A case report. <i>Pain Pract.<\/i> 14: E85\u2013E90.","DOI":"10.1111\/papr.12133"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Tamura, M., Aizawa, R., Hori, M. and Ozaki, H. 2009. Progressive renal dysfunction and macrophage infiltration in interstitial fibrosis in an adenine-induced tubulointerstitial nephritis mouse model. <i>Histochem. Cell Biol.<\/i> 131: 483\u2013490.","DOI":"10.1007\/s00418-009-0557-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tankersley, D. L., Preston, M. S. and Finlayson, J. S. 1988. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. <i>Mol. Immunol.<\/i> 25: 41\u201348.","DOI":"10.1016\/0161-5890(88)90088-0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Teeling, J. L., Jansen-Hendriks, T., Kuijpers, T. W., de Haas, M., van de Winkel, J. G., Hack, C. E. and Bleeker, W. K. 2001. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. <i>Blood<\/i> 98: 1095\u20131099.","DOI":"10.1182\/blood.V98.4.1095"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Wagner, R. and Myers, R. R. 1996. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. <i>Neuroreport<\/i> 7: 2897\u20132901.","DOI":"10.1097\/00001756-199611250-00018"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Weller, A. H., Hall, M. and Huber, S. A. 1992. Polyclonal immunoglobulin therapy protects against cardiac damage in experimental coxsackievirus-induced myocarditis. <i>Eur. Heart J.<\/i> 13: 115\u2013119.","DOI":"10.1093\/oxfordjournals.eurheartj.a060030"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Yamamoto, W., Mikami, T. and Iwamura, H. 2008. Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. <i>Eur. J. Pharmacol.<\/i> 583: 56\u201361.","DOI":"10.1016\/j.ejphar.2008.01.010"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Zelenka, M., Schafers, M. and Sommer, C. 2005. Intraneural injection of interleukin-1beta and tumor necrosis factor-alpha into rat sciatic nerve at physiological doses induces signs of neuropathic pain. <i>Pain<\/i> 116: 257\u2013263.","DOI":"10.1016\/j.pain.2005.04.018"}],"container-title":["Journal of Veterinary Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/78\/1\/78_15-0195\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:08:49Z","timestamp":1748592529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/78\/1\/78_15-0195\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1292\/jvms.15-0195","relation":{},"ISSN":["0916-7250","1347-7439"],"issn-type":[{"type":"print","value":"0916-7250"},{"type":"electronic","value":"1347-7439"}],"subject":[],"published":{"date-parts":[[2016]]}}}